OCC Trading, page-1230

I disagree with a few forward things in Bell's analysis, including their Striate forward sales call, but that does not matter, much of that speculative opinion. What matters is that finally Bells are covering OCC, per roughie12's post above. I am just grateful they correctly defined the business . Thanks again @roughie12.

Have said a hundred times on here, until OCC gets coverage from a major broker it will never attract Institutional money. Its just the way the Australian equity market structured. I've been out there in the past trying to push with a few industry contacts, but bio-tech analyst coverage in Australia is crap.

Insto' money will only climb on board when they get professional coverage and the business shows potential of being cash positive in the future. It seems, FINALLY, OCC is showing that promise.

I thought coverage would have come with the Channel 7 exposure, but it took the BioHorizons deal, with the usual delay, that also likely sees positive cash flow for OCC in the near future (medium term more likely in Bell's estimation, I disagree).